Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy Worldwide

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Shilpa-Medicare-NAFLD

More Like This

PR Newswire associated0

Shilpa Medicare Secures SEC-CDSCO Nod for Nor-Ursodeoxycholic Acid Tablets, Eyes Market Launch for NASH

Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis

PR Newswire associated0

Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics

PR Newswire associated0

Shilpa Medicare Makes History: First Indian Company Completes Phase 1 Trial for Recombinant Human Albumin (rHA) 20%

Navamedic ASA: National approvals of Flexilev® in OraFID® granted across all Nordic countries

Navamedic ASA: First approval of the medical device OraFID® as primary package for a pharmaceutical product

PR Newswire associated0

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC